United States: Patents For Computer And Life Science Technologies Making A Comeback?

Last Updated: November 18 2016
Article by Dorothy R. Auth and Howard Wizenfeld

Most Read Contributor in United States, March 2019

In recent years, the U.S. Supreme Court has significantly shifted its attention in patent cases to the law regarding patent-eligible subject matter under 35 U.S.C. §101, making it more difficult to obtain and enforce patent protection for computer- and life-science- related technologies. Section 101 precludes patent protection for particular subject matters—i.e., laws of nature, natural phenomena and abstract ideas—and the Supreme Court's precedent has extended this exclusion to many cutting- edge technologies. Stakeholders have become alarmed that patent protection for foundational technologies is in jeopardy. Their concern is well founded.

Very few courts have upheld the validity of patent claims directed to computer-related technologies since the Supreme Court's shift. In fact, many district court judges have dismissed cases based on patent ineligibility even before the claim language has been construed or any facts considered. Similarly, life science patents have been held invalid as covering laws of nature or natural phenomena.

Such a trend could have serious implications on America's ability to be competitive in the global marketplace at a time when high-tech and biotech advances constitute major areas of innovation. However, two recent Federal Circuit cases (Rapid Management Litigation and McRO) suggest there may be reasonable boundaries on the court's principles for excluding patent protection. These recent decisions provide clues on how to draft claims that can survive a §101 challenge thereby allowing stakeholders to obtain and enforce patent claims that comport with the Supreme Court's jurisprudence under §101.

Supreme Court Takes Action

In 2012, the Supreme Court took up the issue of patent eligibility in Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289 (2012). It was a time when the court had—a few years earlier—held that certain patent claims to business methods were not patent-eligible because they were directed to an abstract idea. See Bilski v. Kappos, 561 U.S. 593 (2010). Now the court was seeing additional problems with patents and patent litigants. First, many patent suits were originating with non-producing entities who made aggressive patent licensing and litigation threats a part of their business model. Second, it was a time when many commentators questioned the quality of patents being granted by the U.S. Patent and Trademark Office.

The Mayo case addressed claims directed to a patient taking a specified amount of medication based on the concentration of metabolites found in the patient's body. The question presented to the court was whether these claims are patent-eligible under 35 U.S.C. §101.1

Reasoning that the connection between metabolite level and the necessary amount of medication involved a law of nature, the Supreme Court ruled that these claims were not patent-eligible. Specifically because the claims were directed to "well-understood, routine, conventional activity previously engaged in by researchers in the field" with the simple further instruction to apply it, the claims were held not patenteligible. Significantly more than simply reciting a natural law and adding the words "apply it" must be claimed to be patent-eligible.

Less than a year later, the Supreme Court addressed patent eligibility in Myriad Ass'n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107 (2013). The patentee in Myriad asserted claims directed to certain isolated naturally occurring DNA sequences known as BRCA1 and BRCA2 and methods of using the sequences to diagnose breast cancer. The court held those claims invalid as patent-ineligible. However, in dicta, the Supreme Court left open the door to patents directed to "new applications of knowledge" stating that such applications of knowledge could be patent-eligible.

The following year, the Supreme Court clarified the principle set out in Mayo with a two-step test to analyze patent claims for compliance with 35 U.S.C. §101 in Alice Corp. Pty. v. CLS Bank Int'l, 134 S. Ct. 2347 (2014). The first step of this test inquired whether the claim at issue is "directed to" one of the exceptions to patent eligibility, such as an abstract idea. If so, then step two would determine whether the claims—both their individual elements and as a whole—contain an "'inventive concept'" sufficient to "'transform the nature of the claim' into a patent-eligible application." Using this two-step test, the court held that "if a patent's recitation of a computer amounts to a mere instruction to 'implement' an abstract idea 'on a computer,' that addition cannot impart patent eligibility." The Alice ruling had a significant impact on computer-related patents, putting the industry on notice that it can no longer rely on patent protection for methods of doing business by using a general purpose computer.

Fallout for Industries

Both the high-tech and life sciences industries have been seriously affected by these holdings.

Since the Alice decision in June 2014, there have been 137 computer- implemented method patents that have been invalidated by the district courts. Of those 137 invalidated patents, 44 were invalidated pursuant to a motion to dismiss on the pleadings, 48 were invalidated pursuant to a motion for summary judgment, and 45 were invalidated by a district court judge after conducting a trial. Thus, of the high-tech patents asserted in litigation, 57 percent have been found invalid as directed to patentineligible subject matter.2 Further, 75 percent of these decisions were affirmed by the Federal Circuit.3

Post-Alice, the major question for those in the high-tech industry has been whether the courts might use Alice to strike down the entire class of patents as patent-ineligible for merely reciting process steps implemented on a computer. The Supreme Court decisions have raised similar concerns among life sciences companies that rely heavily on patent protection to justify commercial development of a new product. The holdings have clouded the validity of thousands of already-granted U.S. patents and materially affected the strategy companies follow to protect potential biologic product candidates.

Even the dicta in Myriad, which left a faint hope alive that claims covering the application of natural phenomenon (and even isolated compounds) may be patent-eligible was dashed when a claim directed to an application of a natural phenomenon was struck down as patent-ineligible. See Ariosa Diagnostics v. Sequenom, 788 F.3d 1371, reh'g en banc denied, 809 F.3d 1282 (Fed. Cir. 2015) (per curiam), cert. denied, 136 S. Ct. 2511 (2016). The claims in Ariosa were directed to the specific application of extracting, amplifying and detecting paternal cell-free fetal DNA in maternal serum.

Although the Federal Circuit denied a rehearing in Ariosa, Judge Pauline Newman dissented, arguing that the Supreme Court's precedent did not warrant invalidating the Ariosa claims. Relying on the Supreme Court's interpretation of §101 based on preemption, Judge Newman reasoned that per Myriad "patenting of this new diagnostic method" was patent-eligible because it did not "preempt further study of this science."

New Hope

For many, Ariosa has been a low point for patent eligibility. Recently, the Federal Circuit has showed signs of moving away from a restrictive reading and has instead moderated its view of § 101, providing new hope to patentees in both the life- sciences and high-tech fields. The Federal Circuit has begun analyzing the first Alice step by focusing on whether the claimed subject matter preempts the claimed field to produce a more balanced legal framework for determining patent eligibility.

In one recent Federal Circuit case, Rapid Litigation, the claims at issue were directed to using a specific process for repeatedly freezing and thawing liver cells to produce a set of viable cells. See Rapid Litig. Mgmt. v. Cellzdirect, 827 F.3d 1042 (Fed. Cir. 2016). Although the district court found the claims invalid as claiming a law of nature, the Federal Circuit reversed stating that under step one of the two-step test, the claims are directed to more than just multiple cycles of freezing and thawing liver cells and thus do not preempt a law of nature.

When looking to the claim as a whole, the court stated: "The claims are directed to a new and useful method preserving hepatocyte cells. Indeed, the claims recite a 'method of producing a desired preparation of multi-cryopreserved hepatocytes'" and that, according to the specification, "achieves a better way of preserving hepatocytes" than other known methods. Because the claims specifically recited the technical improvement, the Federal Circuit found other methods would not be preempted and thus found step one had been satisfied.

Similarly, the Federal Circuit in McRO clarified its stance on whether software-related inventions were eligible for protection, answering in the affirmative to the relief of many in the high-tech field. McRO v. Bandai Namco Games Am., No. 15-1080, 2016 WL 4896481(Fed. Cir. Sept. 13, 2016). Here too, the Federal Circuit found that the claims were not directed to an abstract idea under step one of the test and therefore were patent-eligible.

McRO's patent claims were directed to automating 3-D animation by using a particular set of rules which provided an advancement over known methods. As explained in the specification, 3-D animation uses multiple 3-D models of a character's face to depict various facial expressions made during speech. Using prior methods, an animator had to manually determine how to morph the character's face between the various 3-D models of facial expression.

Applying the two-step test as articulated in Rapid Litigation, the Federal Circuit found the claims required more than the abstract idea of using any rules-based approach to animate 3-D models. Indeed, the recited rules themselves had specific requirements that did not "preemp[t] all techniques for automating 3-D animation that rely on rules" and thus the claims were patent-eligible subject matter.

Post-Alice, Mayo and Myriad

Given the recent Rapid Litigation and McRO decisions, the Federal Circuit seems to have provided a more balanced framework to assess patent eligibility. The common theme running through both Rapid Litigation and McRO is that the specification must explain the technical improvements which in turn must be specifically recited in the claims. In addition, as McRO points out, even generic claims may be patent-eligible so long as the claims specifically recite the necessary steps or rules and do not preempt all other techniques in the claimed field.

Finally, the court's current focus on recitation of technical improvements and on consideration of what the claims are "directed to" may be a signal that the Federal Circuit may be gently shifting its focus to analyzing claims under other statutory provisions addressing novelty and enablement.


1. The patent laws of the United States define patent-eligible subject matter under §101 as "any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof." Although expansive, the language of §101 is not limitless. The Supreme Court has read §101 as excluding from patent protection "laws of nature, natural phenomena, and abstract ideas." Diamond v. Diehr, 450 U.S. 175 (1981). The reason for this exclusionary principle stems from a concern of preemption. See Alice Corp. Pty. v. CLS Bank Int'l, 134 S. Ct. 2347 (2014). Laws of nature (like gravity), natural phenomena (like the DNA sitting in our chromosomes), and abstract ideas (like mathematical algorithms) are the "building blocks of human ingenuity" and therefore may not be used by one for all purposes. Id. Monopolization of these tools by the grant of a patent might tend to impede innovation more than it would tend to promote it, thereby thwarting the primary object of the patent laws.

2. The statistics are based on research by LegalMetric, a legal research company, in a paper titled "Patent Eligibility Win Rates post- Alice to June 2016."

3. The statistics are based on research by LegalMetric, in a paper titled "Percentage of Patent Ineligibility Decisions Affirmed June 2014 to October 2016."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Practice Guides
by Mondaq Advice Centers
Relevancy Powered by MondaqAI
United States
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions